Anaphylaxis following administration of intravenous methylprednisolone sodium succinate in a renal transplant recipient.
Methylprednisolone sodium succinate (MPS) is widely used in the management of renal transplantation. Of interest is the rare occurrence of anaphylaxis and anaphylactoid reaction to MPS. We report on a patient who developed anaphylaxis following the intravenous administration of MPS during a renal transplant operation. Intracutaneous testing was carried out with MPS and a strong positive reaction was observed. Histamine and tryptase concentrations were high after the anaphylactic reaction. Including the present case, there have been 13 reports of anaphylactic or anaphylactoid reactions to MPS, occurring in renal transplant recipients. Clinicians should be aware of the potential risk of MPS administration. If transplant patients undergo skin testing against MPS prior to transplant, they may benefit from an alternative medication with other corticosteroids. To use MPS without severe adverse reactions, lower administration rates and dosages are very important.
Saito
Ryoichi
R
Departments of Urology, Kouka Public Hospital, Shiga Kobe City Central Hospital, Hyogo Kyoto National Hospital Faculty of Medicine, Kyoto University, Kyoto, Japan. kouka-uro@proof.ocn.ne.jp
Moroi
Seiji
S
Okuno
Hiroshi
H
Ogawa
Osamu
O
D000328:Adult; D000707:Anaphylaxis / Q000139:chemically induced*; D006801:Humans; D007275:Injections, Intravenous; D016030:Kidney Transplantation; D008297:Male; D008776:Methylprednisolone Hemisuccinate / Q000008:administration & dosage / Q000009:adverse effects*
D008776:Methylprednisolone Hemisuccinate